Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

This stock is priced like a company close to bankruptcy. We hit the final private placement offering price of $.40 today.

While no biotech is a sure thing (including BPTH) we are in much better position with positive trial results and 9 million in the bank then when the final private placement happened. To me this decline is all about the Russell reconstitution but certainly the company's failure to provide any meaningful update regarding the status of the phase II trial enrollment has also played a roll.

In PN's most recent Q update he use the term "pace" to define enrollment and confirmed BPTH is on pace to have 19 patients evaluated by year's end. If so, it is hard justify this PPS unless the trial results have turned negative, which would surprise us all.